A Sign Of Long-Term Improvement Of ANDA Review Process

Law360, New York (February 12, 2014, 3:45 PM EST) -- On Jan. 23, the U.S. Food and Drug Administration announced the establishment of a public docket for comments on improving the completeness and quality of abbreviated new drug application submissions to the agency. Specifically, the FDA is asking how it can reduce the occurrence of common deficiencies in the following aspects: filing, chemistry, sterility, bioequivalence, fatal flaws and drug master files.

The FDA is asking about the difficulties that sponsors experience, and is also seeking input on how to best share its own suggestions to improving...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.